Drug Screening Market Report 2026

Drug Screening Market Overview

• Drug Screening market size has reached to $9.72 billion in 2025 • Expected to grow to $19.2 billion in 2030 at a compound annual growth rate (CAGR) of 14.5% • Growth Driver: Increasing Drug And Alcohol Usage • Market Trend: Strategic Partnerships And Collaborations Among Market Players • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Drug Screening Market?

Drug screening is an approach used for drug testing, identified and optimized for clinical trials used in the analysis of blood, urine, hair, or saliva to detect the presence of chemicals and pollutants and other illicit substance left in the body as a result of drug usage. The main types of drug screening products include rapid testing devices, consumables, and others. Rapid testing devices refer to easy-to-use drug screening devices that provide results quicker than the standard traditional laboratory test. The different samples used in drug screening includes oral fluid sample, hair sample, urine sample, breath sample, and others. They are used in drug testing laboratories, workplaces, criminal justice and law enforcement, hospitals, drug treatment centers, individual users, pain management centers, schools & colleges.

What Is The Drug Screening Market Growth Forecast?

The drug screening market size is expected to see rapid growth in the next few years. It will grow to $19.2 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing adoption of ai-enabled screening analytics, rising demand for portable drug testing devices, expansion of regulatory drug compliance testing, growing use of real-time reporting systems, innovation in multi-panel drug screening. Major trends in the forecast period include increasing adoption of rapid drug testing kits, rising use of automated laboratory screening systems, growing integration of digital reporting solutions, expansion of point-of-care drug testing, enhanced focus on high-accuracy detection.

Global Drug Screening Market Segmentation

1) By Products: Rapid Testing Devices, Consumables, Other Products 2) By Sample Type: Oral Fluid Sample, Hair Sample, Urine Sample, Breath Sample, Other Sample Types 3) By End User: Drug Testing Laboratories, Workplaces, Criminal Justice and Law Enforcement Agencies, Hospitals, Drug Treatment Centers, Individual Users, Pain Management Centers, Schools and Colleges Subsegments: 1) By Rapid Testing Devices: Urine Drug Test Kits, Saliva Drug Test Kits, Blood Drug Test Devices, Instant Test Strips 2) By Consumables: Reagents and Assays, Sample Collection Devices, Calibration Standards 3) By Other Products: Laboratory Equipment, Software Solutions, Storage and Transport Solutions

What Is The Driver Of The Drug Screening Market?

Growing drug and alcohol consumption is expected to propel the growth of the drug screening market going forward. Drug addiction is a disease that affects a person's brain and behavior, resulting in the inability to control the use of a legal or illegal drug or medication. Substances such as alcohol, marijuana, and nicotine also are considered drugs. As drug and alcohol addiction increases, the chances of disease are higher, which triggers the need for drug screening. For instance, in June 2025, according to the United Nations Office on Drugs and Crime, an Austria-based United Nations office, 316 million people used a drug (excluding alcohol and tobacco) in 2023, or six percent of the population aged between 15 and 64. With 244 million users, cannabis remains the most widely used drug, followed by opioids (61 million), amphetamines (30.7 million), cocaine (25 million), and “ecstasy” (21 million). Therefore, growing drug and alcohol consumption is driving the growth of the drug screening industry during the forecast period.

Key Players In The Global Drug Screening Market

Major companies operating in the drug screening market are Laboratory Corporation, Quest Diagnostics Incorporated, OraSure Technologies Inc., Alfa Scientific Designs Inc., Abbott Laboratories, Thermo Fisher Scientific Inc., Drägerwerk AG & Co. KGaA, LifeLoc Technologies Inc., MPD Inc., Omega Laboratories Inc., Premier Biotech Inc., Psychemedics Corporation, F. Hoffmann-La Roche Ltd., Shimadzu Corporation, Siemens Healthineers AG, Medtox Scientific Inc., American Screening Corporation, Clinical Reference Laboratory Inc., Express Diagnostics International Inc., Global Drug Testing Services, Kroll Laboratory Specialists Inc., Medscreen Laboratories, National Screening Centers Inc., American Bio Medica Corporation, Mayo Clinic Laboratories, ACM Global Laboratories, Intertek Group plc, Eurofins Scientific SE

Global Drug Screening Market Trends and Insights

Major companies operating in the drug screening market are increasingly focusing on strategic partnerships and collaborations to improve their financial strength, strengthen their product portfolio, and expand their geographical presence. A strategic collaboration refers to an agreement between two or more parties to pursue a set of agreed-upon objectives while remaining independent organizations. For instance, in February 2025, Neopharma Technologies, a Canada-based drug testing company, and Impairment Science, a United States-based cognitive assessment company, announced a strategic partnership aimed at revolutionizing drug and impairment testing. The collaboration combines Neopharma’s NEOVAULT platform, which digitally reads and reports rapid drug test results, with Impairment Science’s DRUID cognitive impairment assessment, an AI-driven tool for evaluating functional impairment. By integrating these two technologies, the partnership aims to enhance the accuracy and relevance of drug screening, providing real-time insights not only on drug presence but also on functional impairment. This collaboration could potentially improve workplace safety, regulatory compliance, and safety-sensitive decision-making by leveraging AI and digital reporting technologies.

What Are Latest Mergers And Acquisitions In The Drug Screening Market?

In June 2024, Premier Biotech, a US-based provider of urine and oral fluid drug testing solutions and toxicology services, acquired Desert Tox, LLC, for an undisclosed amount. With this acquisition, Premier Biotech aims to expand its laboratory testing capacity, strengthen its presence in the oral-fluid drug testing market, and broaden its national customer base across workplace, government, and occupational health segments. Desert Tox, LLC is a US-based provider of SAMHSA-certified urine and oral-fluid drug testing services for employment, government, and clinical clients.

Regional Outlook

North America was the largest region in the drug screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the drug screening market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Drug Screening Market?

The drug screening market consists of sales of testing kits, reagents, and other supplies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.